Sharvil Patil
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sharvil Patil has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Anant Paradkar
University of Bradford
9 shared publications Kakasaheb Mahadik
Department of Pharmaceutics, Bharati Vidyapeeth Deemed University, Poona College of Pharmacy, Erandwane, India
8 shared publicationsSuresh Bhat
Polymer Science and Engineering Division, CSIR-National Chemical Laboratory, Pashan, Pune, India
6 shared publicationsEdakkal Venugopal
Polymer Science and Engineering Division, National Chemical Laboratory, Pune, 411 008, India
4 shared publications- Kakasaheb Ramoo Mahadik
Bharati Vidyapeeth Deemed University
4 shared publications Kakasaheb R. Mahadik
Department of Pharmaceutics, Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Pune, Maharashtra, India
3 shared publications
Latest Publications
- 15 January 2026
- Published by Springer Nature in Pharmaceutical Research
- Vol. 43 (3) , 927-939
Novel Cocrystal of Quercetagetin: In vitro and in vivo Insights into Biopharmaceutical Performance
Purpose Quercetagetin (QTGN) is a naturally occurring flavonol predominantly sourced from marigold flowers and possesses notable therapeutic potential, including antidiabetic, anticancer, antioxidant, anti-inflammatory, and antiviral properties. However, poor aqueous solubility and in turn bioavailability restrict therapeutic utility of QTGN. Crystal engineering is one of the approaches proven to be fruitful in resolving the solubility issues of many active pharmaceutical ingredients (APIs). Method In the present work, a cocrystal of QTGN using betaine (BET) as coformer viz. Quercetagetin⋅betaine⋅ethanol (QTGN⋅BET⋅EtOH) was synthesized using the solvent evaporation method. It was further characterized using Fourier Transform Infrared Spectroscopy (FTIR), Differential Scanning Calorimetry (DSC), Thermogravimetric analysis (TGA), Powder X-ray diffraction (PXRD), and single crystal XRD (SCXRD). Result FTIR studies confirmed hydrogen bonding between QTGN and BET. PXRD studies showed formation of new crystalline phase. The prepared cocrystal had stoichiometric ratio of 1:1:1 between QTGN, BET, and ethanol forming cocrystal ethanolate and shared robust hydroxyl⋯carboxylate supramolecular synthon as confirmed by TGA and SCXRD, respectively. Equilibrium solubility study and in vitro dissolution study showed a significant improvement (p < 0.0001) in aqueous solubility of QTGN upon its cocrystallization with BET. Furthermore, in vivo pharmacokinetic study revealed a 1.28-fold increase in bioavailability of QTGN when formulated as cocrystal solvate. The prepared cocrystal was found to be stable over a period of six months at 40°C and 75% RH when analyzed using PXRD studies. Conclusion The current work represents a frontier in pharmaceutical formulation, providing a means to fully harness the therapeutic potential of QTGN using cocrystal approach. Graphical Abstract
- 15 January 2026
- Published by Springer Nature in Pharmaceutical Research
- Vol. 43 (3) , 927-939
Novel Cocrystal of Quercetagetin: In vitro and in vivo Insights into Biopharmaceutical Performance
Purpose Quercetagetin (QTGN) is a naturally occurring flavonol predominantly sourced from marigold flowers and possesses notable therapeutic potential, including antidiabetic, anticancer, antioxidant, anti-inflammatory, and antiviral properties. However, poor aqueous solubility and in turn bioavailability restrict therapeutic utility of QTGN. Crystal engineering is one of the approaches proven to be fruitful in resolving the solubility issues of many active pharmaceutical ingredients (APIs). Method In the present work, a cocrystal of QTGN using betaine (BET) as coformer viz. Quercetagetin⋅betaine⋅ethanol (QTGN⋅BET⋅EtOH) was synthesized using the solvent evaporation method. It was further characterized using Fourier Transform Infrared Spectroscopy (FTIR), Differential Scanning Calorimetry (DSC), Thermogravimetric analysis (TGA), Powder X-ray diffraction (PXRD), and single crystal XRD (SCXRD). Result FTIR studies confirmed hydrogen bonding between QTGN and BET. PXRD studies showed formation of new crystalline phase. The prepared cocrystal had stoichiometric ratio of 1:1:1 between QTGN, BET, and ethanol forming cocrystal ethanolate and shared robust hydroxyl⋯carboxylate supramolecular synthon as confirmed by TGA and SCXRD, respectively. Equilibrium solubility study and in vitro dissolution study showed a significant improvement (p < 0.0001) in aqueous solubility of QTGN upon its cocrystallization with BET. Furthermore, in vivo pharmacokinetic study revealed a 1.28-fold increase in bioavailability of QTGN when formulated as cocrystal solvate. The prepared cocrystal was found to be stable over a period of six months at 40°C and 75% RH when analyzed using PXRD studies. Conclusion The current work represents a frontier in pharmaceutical formulation, providing a means to fully harness the therapeutic potential of QTGN using cocrystal approach. Graphical Abstract
- Open Access
- 14 January 2026
- Published by Royal Society of Chemistry (RSC) in RSC Pharmaceutics
- Vol. 3 (3) , 701-710
A simple and cost-effective chrysin–theophylline eutectic: enhanced solubility, dissolution, and oral bioavailability with potential for respiratory applications
Chrysin–Theophylline eutectic enhances aqueous solubility, dissolution, and oral bioavailability of Chrysin, with promising potential for respiratory therapy.
- 14 January 2026
- Published by Royal Society of Chemistry (RSC) in RSC Pharmaceutics
- Vol. 3 (3) , 701-710
Open AccessA simple and cost-effective chrysin–theophylline eutectic: enhanced solubility, dissolution, and oral bioavailability with potential for respiratory applications
Chrysin–Theophylline eutectic enhances aqueous solubility, dissolution, and oral bioavailability of Chrysin, with promising potential for respiratory therapy.
- Open Access
- 15 July 2025
- Published by Elsevier in Next Nanotechnology
- Vol. 8
Posaconazole loaded bilosomes as a novel vesicular carrier for topical treatment of fungal infections: Formulation, optimization, ex-vivo permeation and antifungal assay
- 15 July 2025
- Published by Elsevier in Next Nanotechnology
- Vol. 8
Open AccessPosaconazole loaded bilosomes as a novel vesicular carrier for topical treatment of fungal infections: Formulation, optimization, ex-vivo permeation and antifungal assay
- Open Access
- 6 March 2025
- Published by Royal Society of Chemistry (RSC) in RSC Pharmaceutics
- Vol. 2 (3) , 541-552
Artesunate-loaded bilosomes with enhanced oral bioavailability: in silico and in vitro study against Leishmania donovani promastigotes and in vivo pharmacokinetic assessment in rats
Schematic Illustration of mechanism of antileishmanial activity of artesunate-loaded bilosomes.
- 6 March 2025
- Published by Royal Society of Chemistry (RSC) in RSC Pharmaceutics
- Vol. 2 (3) , 541-552
Open AccessArtesunate-loaded bilosomes with enhanced oral bioavailability: in silico and in vitro study against Leishmania donovani promastigotes and in vivo pharmacokinetic assessment in rats
Schematic Illustration of mechanism of antileishmanial activity of artesunate-loaded bilosomes.
- Open Access
- 30 August 2023
- Published by Elsevier in Journal of Taibah University Medical Sciences
- Vol. 18 (6) , 1511-1518
Fabrication, optimization and characterization of an osmotic push-pull drug delivery system for paliperidone
- 30 August 2023
- Published by Elsevier in Journal of Taibah University Medical Sciences
- Vol. 18 (6) , 1511-1518
Open AccessFabrication, optimization and characterization of an osmotic push-pull drug delivery system for paliperidone
- 2 November 2022
- Published by Taylor & Francis in Analytical Chemistry Letters
- Vol. 12 (6) , 745-760
Hot Melt Extrusion Assisted Felodipine Loaded Liquid Crystal Precursor with Enhanced Solubility and Sustained Drug Release Characteristics
Glyceryl monooleate (GMO) forms cubic mesophase upon hydration with sustained drug release characteristics. However its stickiness and stiffness often creates processing challenges for preparation of formulations. Felodipine (FLD), BCS class II molecule was used as model drug. Thus objective of the current work was to increase manufacturing feasibility of GMO using polymer and to enhance the release of felodipine by preparing LC precursors using HME. HPMC E5 polymer was selected for processing of FLD. Batch optimization was done using 23 Factorial design. The prepared batches were characterized for DSC, FTIR, hot stage microscopy (HSM), plane polarized light microscopy (PPL), PXRD and in vitro dissolution studies. The processing of FLD using HME process showed amorphization as revealed by PXRD studies. DSC and HSM studies showed solubilization of FLD in the molten mass of GMO and HPMC E5 confirming formation of solid dispersion. PPL demonstrated formation of cubic LC phase by GMO upon hydration of prepared formulations. The optimized batch of felodipine showed significant improvement in the dissolution profile of FLD with extended release profile. HME assisted liquid crystal precursors could act as promising formulations for BCS II drugs requiring extended drug release profile with improved processing feasibility of GMO. GRAPHICAL ABSTRACT
- 2 November 2022
- Published by Taylor & Francis in Analytical Chemistry Letters
- Vol. 12 (6) , 745-760
Hot Melt Extrusion Assisted Felodipine Loaded Liquid Crystal Precursor with Enhanced Solubility and Sustained Drug Release Characteristics
Glyceryl monooleate (GMO) forms cubic mesophase upon hydration with sustained drug release characteristics. However its stickiness and stiffness often creates processing challenges for preparation of formulations. Felodipine (FLD), BCS class II molecule was used as model drug. Thus objective of the current work was to increase manufacturing feasibility of GMO using polymer and to enhance the release of felodipine by preparing LC precursors using HME. HPMC E5 polymer was selected for processing of FLD. Batch optimization was done using 23 Factorial design. The prepared batches were characterized for DSC, FTIR, hot stage microscopy (HSM), plane polarized light microscopy (PPL), PXRD and in vitro dissolution studies. The processing of FLD using HME process showed amorphization as revealed by PXRD studies. DSC and HSM studies showed solubilization of FLD in the molten mass of GMO and HPMC E5 confirming formation of solid dispersion. PPL demonstrated formation of cubic LC phase by GMO upon hydration of prepared formulations. The optimized batch of felodipine showed significant improvement in the dissolution profile of FLD with extended release profile. HME assisted liquid crystal precursors could act as promising formulations for BCS II drugs requiring extended drug release profile with improved processing feasibility of GMO. GRAPHICAL ABSTRACT